Normal organ dosimetry for thyroid cancer patients treated with radioiodine as part of the multi-centre multi-national Horizon 2020 MEDIRAD project

[1]  M. Luster,et al.  Second primary malignancies induced by radioactive iodine treatment of differentiated thyroid carcinoma — a critical review and evaluation of the existing evidence , 2022, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  M. Schlumberger,et al.  Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer. , 2022, The New England journal of medicine.

[3]  H. Scherthan,et al.  DNA damage and repair in peripheral blood mononuclear cells after internal ex vivo irradiation of patient blood with 131I , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  G. Flux,et al.  Adjustment of the iodine ICRP population pharmacokinetic model for the use in thyroid cancer patients after thyroidectomy , 2021, Journal of radiological protection : official journal of the Society for Radiological Protection.

[5]  D. Andreadis,et al.  Sialadenitis as a complication of radioiodine therapy in patients with thyroid cancer: where do we stand? , 2021, Hormones.

[6]  N. Lanconelli,et al.  In Silico Validation of MCID Platform for Monte Carlo-Based Voxel Dosimetry Applied to 90Y-Radioembolization of Liver Malignancies , 2021, Applied Sciences.

[7]  E. Miles,et al.  Recommendations for Multicentre Clinical Trials Involving Dosimetry for Molecular Radiotherapy , 2020, Clinical oncology (Royal College of Radiologists (Great Britain)).

[8]  A. Buck,et al.  Setting up a quantitative SPECT imaging network for a European multi-centre dosimetry study of radioiodine treatment for thyroid cancer as part of the MEDIRAD project , 2020, EJNMMI Physics.

[9]  Damian Borys,et al.  OpenDose: Open-Access Resource for Nuclear Medicine Dosimetry , 2020, The Journal of Nuclear Medicine.

[10]  Iain Murray,et al.  Standardised quantitative radioiodine SPECT/CT Imaging for multicentre dosimetry trials in molecular radiotherapy , 2019, Physics in medicine and biology.

[11]  G. Flux,et al.  Physics aspects of setting up a multi-centre clinical trial involving internal dosimetry of radioiodine treatment of differentiated thyroid cancer. , 2019, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[12]  A. Hackshaw,et al.  Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial , 2019, The lancet. Diabetes & endocrinology.

[13]  C. Buchpiguel,et al.  Effects of Thyroid Hormone Withdrawal and Recombinant Human Thyrotropin on Glomerular Filtration Rate During Radioiodine Therapy for Well-Differentiated Thyroid Cancer. , 2015, Thyroid : official journal of the American Thyroid Association.

[14]  Icrp.  ICRP Publication 128: Radiation Dose to Patients from Radiopharmaceuticals: a Compendium of Current Information Related to Frequently Used Substances , 2015 .

[15]  A. Vissink,et al.  World Workshop on Oral Medicine VI: clinical implications of medication-induced salivary gland dysfunction. , 2015, Oral surgery, oral medicine, oral pathology and oral radiology.

[16]  W Bolch,et al.  ICRP Publication 128: Radiation Dose to Patients from Radiopharmaceuticals: a Compendium of Current Information Related to Frequently Used Substances , 2015, Annals of the ICRP.

[17]  George Loudos,et al.  A review of the use and potential of the GATE Monte Carlo simulation code for radiation therapy and dosimetry applications. , 2014, Medical physics.

[18]  R. Kikinis,et al.  3D Slicer as an image computing platform for the Quantitative Imaging Network. , 2012, Magnetic resonance imaging.

[19]  J. Franklyn,et al.  Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. , 2012, The New England journal of medicine.

[20]  M. Schlumberger,et al.  Strategies of radioiodine ablation in patients with low-risk thyroid cancer. , 2012, The New England journal of medicine.

[21]  R. Tian,et al.  Iodine kinetics and dosimetry in the salivary glands during repeated courses of radioiodine therapy for thyroid cancer. , 2011, Medical physics.

[22]  M. Luster,et al.  The absorbed dose to the blood is a better predictor of ablation success than the administered 131I activity in thyroid cancer patients , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  Carlo Chiesa,et al.  EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  Glenn D. Flux,et al.  A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[25]  A. Bockisch,et al.  Pre-therapeutic 124I PET(/CT) dosimetry confirms low average absorbed doses per administered 131I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  S. Mandel,et al.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[27]  F. Saran,et al.  Whole-Body Dosimetry for Individualized Treatment Planning of 131I-MIBG Radionuclide Therapy for Neuroblastoma , 2009, Journal of Nuclear Medicine.

[28]  S. Straus,et al.  Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. , 2009, Thyroid : official journal of the American Thyroid Association.

[29]  Stephen R. Thomas,et al.  MIRD Pamphlet No. 21: A Generalized Schema for Radiopharmaceutical Dosimetry—Standardization of Nomenclature , 2009, Journal of Nuclear Medicine.

[30]  W. Oyen,et al.  Guidelines for radioiodine therapy of differentiated thyroid cancer , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[31]  A. Gafni,et al.  Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis. , 2007, Thyroid : official journal of the American Thyroid Association.

[32]  Markus Luster,et al.  Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  H. Maxon,et al.  Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer. , 1997, Thyroid : official journal of the American Thyroid Association.

[34]  V. R. McCready,et al.  Radiation dose assessment in radioiodine therapy. Dose-response relationships in differentiated thyroid carcinoma using quantitative scanning and PET. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[35]  M. Ranney,et al.  Beyond the bedside: Clinicians as guardians of public health, medicine and science , 2020, The American Journal of Emergency Medicine.

[36]  Alex Gil.  Implementation of a clinical dosimetry workflow to perform personalized dosimetry for internal radiotherapy. (Mise en œuvre d'un flux de travail de dosimétrie clinique pour réaliser une dosimétrie personnalisée pour la radiothérapie interne vectorisée) , 2022 .

[37]  J. Spaltenstein,et al.  A semantic database for integrated management of image and dosimetric data in low radiation dose research in medical imaging , 2020, AMIA.

[38]  S. Thang,et al.  Radioiodine Therapy for Well-Differentiated Thyroid Cancer , 2018 .

[39]  Kaliszewski,et al.  American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer : The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer , 2017 .

[40]  P. Mildenberger,et al.  Development of an IHE MRRT-compliant open-source web-based reporting platform , 2016, European Radiology.

[41]  Kirby G. Vosburgh,et al.  3D Slicer: A Platform for Subject-Specific Image Analysis, Visualization, and Clinical Support , 2014 .

[42]  J. Humm,et al.  Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.